Reuters logo
BRIEF-Tracon Pharmaceuticals announces completion of enrollment in randomized phase 2B traxar study of TRC105 and Inlyta in renal cell carcinoma
September 7, 2017 / 12:25 PM / 3 months ago

BRIEF-Tracon Pharmaceuticals announces completion of enrollment in randomized phase 2B traxar study of TRC105 and Inlyta in renal cell carcinoma

Sept 7 (Reuters) - Tracon Pharmaceuticals Inc

* Tracon Pharmaceuticals announces completion of enrollment in randomized phase 2B Traxar study of TRC105 and Inlyta in renal cell carcinoma

* Tracon expects to report top-line progression-free survival (PFS) data from study later this year Source text for Eikon: Further company coverage:

Our Standards:The Thomson Reuters Trust Principles.
0 : 0
  • narrow-browser-and-phone
  • medium-browser-and-portrait-tablet
  • landscape-tablet
  • medium-wide-browser
  • wide-browser-and-larger
  • medium-browser-and-landscape-tablet
  • medium-wide-browser-and-larger
  • above-phone
  • portrait-tablet-and-above
  • above-portrait-tablet
  • landscape-tablet-and-above
  • landscape-tablet-and-medium-wide-browser
  • portrait-tablet-and-below
  • landscape-tablet-and-below